chronic lymphocytic leukaemia

News

Lilly gets approval for earlier use of Jaypirca in CLL

Eli Lilly's fast-growing Jaypirca has won a new FDA approval as an earlier treatment for relapsed/refractory chronic lymphocytic leukaemia.

News

Filmmaker helps AbbVie spread the word about leukaemia

AbbVie has turned to an award-winning documentary director to help it highlight the lives of people living with chronic lymphocytic leukaemia.

News

Lilly eyes earlier use of blood cancer drug Jaypirca

Lilly's fast-growing blood cancer drug Jaypirca could gain more momentum thanks to a trial suggesting it could move into the first-line setting.

News

AbbVie files to move Venclexta combo into the CLL front line

AbbVie has filed for FDA approval of a new front-line therapy for chronic lymphocytic leukaemia that it thinks could be 'practice changing."

News

AZ claims EU approval for new Calquence regimens in CLL

AstraZeneca has secured a key approval for its BTK inhibitor Calquence in Europe, currently facing a strong challenge from BeOne's rival Brukinsa.

News

AMPLIFY results dial up Calquence's potential in CLL

AstraZeneca's Calquence has hit the mark in the phase 3 AMPLIFY trial in chronic lymphocytic leukaemia (CLL), a study that chief executive Pascal Soriot recently said could be a "blockbuste

Lilly gets approval for earlier use of Jaypirca in CLL

Filmmaker helps AbbVie spread the word about leukaemia

Lilly eyes earlier use of blood cancer drug Jaypirca

AbbVie files to move Venclexta combo into the CLL front line

AZ claims EU approval for new Calquence regimens in CLL

AMPLIFY results dial up Calquence's potential in CLL

Iambic prices its IPO, seeking to raise up to $160m

Discover a new era of healthcare panel engagement: Grounded ...

chronic lymphocytic leukaemia

Editor's Picks